Evidence map›Paper›PMID 37488080›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2023

[Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus 
Disease 2019 Pneumonia in Lung Cancer Patients: 
A Single-center Retrospective Study].

Wanjun Lu, Jiawen Lv, Qin Wang, Yanwen Yao, Dong Wang, Jiayan Chen, Guannan Wu, Xiaoling Gu, Huijuan Li, Yajuan Chen and 4 more

Erratum issuedOpen access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Wanjun LuDepartment of Respiratory and Critical Care, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Jiawen LvDepartment of Respiratory and Critical Care, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Qin WangDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Yanwen YaoDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Dong WangDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Jiayan ChenDepartment of Respiratory and Critical Care, Jinling Hospital, Nanjing Medical University, Nanjing 210002, China.
Guannan WuDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Xiaoling GuDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Huijuan LiDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Yajuan ChenDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Hedong HanDepartment of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
Tangfeng LvDepartment of Respiratory and Critical Care, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Yong SongDepartment of Respiratory and Critical Care, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Ping ZhanDepartment of Respiratory and Critical Care, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Nanjing General Hospital of Nanjing Military Command · CNNanjing Medical University · CNSecond Affiliated Hospital of Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies have shown that the incidence and severity of corona virus disease 2019 (COVID-19) in patients with lung cancer are higher than those in healthy people. At present, the main anti-tumor treatments for lung cancer include surgery, immunotherapy, chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. While the effects of different anti-tumor treatments on the occurrence and severity of COVID-19 pneumonia are not uniform. Therefore, we aimed to describe clinical characteristics and antitumor therapy of patients with lung cancer and COVID-19 pneumonia, and examined risk factors for severity in this population.

methodsFrom December 1, 2022 to February 15, 2023, a retrospective study was conducted in 217 patients diagnosed with COVID-19 and pathologically confirmed lung cancer in the Jinling Hospital. We collected data about patients' clinical features, antitumor treatment regimen within 6 months, and the diagnosis and treatment of COVID-19. Risk factors for occurrence and severity of COVID-19 pneumonia were identified by univariable and multivariable Logistic regression models.

results(1) Among the 217 patients included, 51 (23.5%) developed COVID-19 pneumonia, of which 42 (82.4%) were classified as medium and 9 (17.6%) were classified as severe; (2) Univariate and multivariate analysis revealed overweight (OR=2.405, 95%CI: 1.095-5.286) and intrapulmonary focal radiotherapy (OR=2.977, 95%CI: 1.071-8.274) are risk factors for increasing occurrence of COVID-19 pneumonia, while other therapies are not; (3) Chronic obstructive pulmonary disease (COPD) history (OR=7.600, 95%CI: 1.430-40.387) was more likely to develop severe pneumonia and anti-tumor therapies such as intrapulmonary focal radiotherapy, chemotherapy, targeted therapy and immunotherapy did not increase severity.

conclusionsIntrapulmonary focal radiation therapy within 6 months increased the incidence of COVID-19 pneumonia, but did not increase the severity. However, there was no safety concern for chemotherapy, targeted therapy, surgery and immunotherapy.

Indexed as

COVID-19Lung NeoplasmsPneumoniaHumansIncidenceRetrospective StudiesAntitumor treatmentCorona virus disease 2019Lung neoplasms

Identifiers

PMID37488080
PMCPMC10365958
OpenAlexW4385230832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.